Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

PHASE3RecruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Hereditary Angioedema (HAE)
Interventions
DRUG

Deucrictibant

Deucrictibant extended-release tablet for once daily oral use

Trial Locations (24)

3052

RECRUITING

Study Site, Melbourne

63141

RECRUITING

Study Site, St Louis

90404

RECRUITING

Study Site, Santa Monica

94598

RECRUITING

Study Site, Walnut Creek

Unknown

RECRUITING

Study Site, Melbourne

RECRUITING

Study Site, Perth

RECRUITING

Study Site, Vienna

RECRUITING

Study Site, Sofia

RECRUITING

Study Site, Montreal

RECRUITING

Study Site, Berlin

RECRUITING

Study Site, Frankfurt

RECRUITING

Study Site, Hong Kong

RECRUITING

Study Site, Dublin

RECRUITING

Study Site, Padua

RECRUITING

Study Site, Krakow

RECRUITING

Study Site, Cape Town

RECRUITING

Study Site, Daegu

RECRUITING

Study Site, Seoul

RECRUITING

Study Site, Brighton

RECRUITING

Study Site, Bristol

RECRUITING

Study Site, Cambridge

RECRUITING

Study Site, London

RECRUITING

Study Site, Plymouth

08907

RECRUITING

Study Site, Barcelona

All Listed Sponsors
lead

Pharvaris Netherlands B.V.

INDUSTRY